Background: Angiogenesis is defined as the expansion and remodeling process affecting the vascular network and it occurs in many pathological conditions including cancer. Hepatocellular carcinoma (HCC) is one of the hyper-vascular cancers. Understanding the process of angiogenesis and its regulatory mechanisms are crucial in HCC treatment. Almost all approved systemic therapies used in HCC target the angiogenesis process especially the vascular endothelial growth factor (VEGF) pathway. Studying genetic variations and other factors that affect angiogenesis could allow tailoring systemic therapy with the most benefits to patients. Aim: Investigating the association between the VEGF variant (rs699947) and the progression of HCC was the main target of this study. Methods: A total of 122 subjects were enrolled in this study (64 patients with HCC, 24 patients with cirrhosis and 34 subjects served as a control group). Genotyping of the VEGF gene (rs699947) was performed by tetra primer amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Results: The AA genotype and the A-allele were found to be lower in patients with HCC compared with other groups. In HCC patients, the AA genotype was associated with higher serum albumin and lower total bilirubin level. Conclusion: The variant allele (rs699947) could be considered as a predictive factor for HCC development.